XB130 inhibits healing of diabetic skin ulcers through the PI3K/Akt signalling pathway
Xin-Lin Zhu, Dong-Ying Hu, Wei-Wei Jiang, Tian-Yang Chen, Tian-Cheng Chen, Wan-Qing Liao, Wen-Zhi Lei, Wen-Jie Fang, Wei-Hua Pan, Department of Dermatology, Shanghai Key Laboratory of Medical Mycology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China
Zhao-Xiang Zeng, Department of Vascular Surgery, Department of Vascular Surgery, Changhai Hospital, Navy Medical University, Shanghai 20003, China
Author contributions: Pan WH, Liao WQ, Fang WJ, Lei WZ, and Zhu XL contributed to conceptualization; Zhu XL, Zeng ZX, and Jiang WW contributed to data curation; Zhu XL, Jiang WW, Zeng ZX, Hu DY, Chen TY, Chen TC, Liao WQ, Lei WZ, Fang WJ, and Pan WH contributed to investigation; Zhu XL, Zeng ZX, Jiang WW, Fang WJ, and Pan WH contributed to methodology; Pan WH contributed to project administration; Pan WH, Fang WJ, and Lei WZ contributed to supervision; Zeng ZX, Hu DY, and Zhu XL contributed to visualization; Zhu XL contributed to writing-original draft preparation; Liao WQ, Fang WJ, Pan WH, and Zhu XL contributed to writing-review and editing; Zhu XL, Hu DY, and Zeng ZX contribute equally to this paper.
Supported by the National Natural Science Foundation of China, No. 82272355; and Shanghai Science and Technology Committee, No. 21410750500.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Naval Medical University Medical Ethics Committee (Protocol No: 2020YffiPZ-102).
Conflict-of-interest statement: All the authors have declared no conflict of interest.
Data sharing statement: All data are provided in this study, and raw data can be requested to the corresponding author.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Hua Pan, PhD, Chief Doctor, Department of Dermatology, Shanghai Key Laboratory of Medical Mycology, Changzheng Hospital, Naval Medical University, No. 415 Fengyang Road, Shanghai 200003, China. firstname.lastname@example.org
Received: May 24, 2023
Peer-review started: May 24, 2023
First decision: June 12, 2023
Revised: July 6, 2023
Accepted: August 2, 2023
Article in press: August 2, 2023
Published online: September 15, 2023